Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 23 July, 2003

Xenova Group PLC

R&D Update

Xenova Group PLC
23 July 2003

                                Xenova Group plc

                             AND R&D REORGANISATION

23rd July 2003: Slough, UK, Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) today provided an update on the R&D reorganisation that followed
the cessation of Phase III studies with tariquidar, which was announced on 13th
May 2003.  The implementation of this reorganisation, which included both
headcount reduction and programme prioritisation, is now largely complete. As a
result, Xenova will, going forward, focus on its key later stage clinical
development programmes.  These changes, mainly affecting the research functions
in Cambridge and Slough, will result in a headcount of 66 (down from 107) by the
end of Q3.  More details will be made available at the forthcoming Interim
Results Announcement.

At the time of the announcement of 13th May, it was stated that a detailed
review of the unblinded clinical data on more than 300 patients in the Phase III
trials would occur, and that decisions concerning the further development of
tariquidar in oncology would be made by QLT Inc and Xenova following this
review. The evaluation is continuing and the analysis of P-glycoprotein
expression in the lung cancer studies is still pending.

QLT will also announce that enrolment in the Phase IIb trial for patients with
chemo-refractory breast cancer, which is being carried out at the MD Anderson
Centre, Texas, has now been sufficiently completed at 17 patients. Preliminary
data on the first 11 patients was presented in a poster at this year's ASCO
meeting. To date, one patient has experienced a partial response after
tariquidar was used as an adjunctive treatment to the chemotherapy to which the
patient had not been previously responding.  In addition to the partial
response, three patients have shown stable disease after the second cycle of
treatment and one continues to be stable at the end of cycle four. QLT will not
be enrolling new patients in this trial.

Commenting on the impact of the reorganisation, David Oxlade, CEO of Xenova
Group said, 'We have prioritised resources on the most commercially attractive
of the products in our clinical portfolio and substantially reduced operating
costs. Currently we have nine products in clinical development, of which four
are externally funded programmes.  Going forward, we have de-prioritised the
majority of our in-house preclinical programmes, except where externally funded,
as is the case for the Genentech collaboration on OX-40.'

                                   -- ends --

UK:                                        US:
Xenova Group plc                           Trout Group/BMC Communications
Tel: +44 (0)1753 706600                    Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer    Press: Brad Miles (Ext 17)
                                           Daniel Budwick (Ext 14)
Daniel Abrams, Group Finance Director      Investors: Jonathan Fassberg (Ext 16)
                                           Lee Stern (Ext 22)
Jon Davies, Corporate Communications

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors

About Xenova Group

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange  ND